RecruitingNCT04985487
Regulatory Post-Marketing Surveillance Study for Brolucizumab
Regulatory Post-Marketing Surveillance (rPMS) Study for Brolucizumab(Beovu ® Injection, Beovu ®Prefilled Syringe)
Sponsor
Novartis Pharmaceuticals
Enrollment
3,000 participants
Start Date
Aug 18, 2021
Study Type
OBSERVATIONAL
Conditions
Summary
This study is an open-label, multicenter, single-arm, observational post-marketing surveillance.
Eligibility
Min Age: 18 YearsMax Age: 100 Years
Inclusion Criteria2
- Patients aged ≥18 years with nAMD that are prescribed with Brolucizumab as per approved local product information
- Patients who consent to participate in the study after the purpose and nature of the study have clearly explained to them (written informed consent)
Exclusion Criteria2
- Contraindications as per local prescribing information 1) Hypersensitivity to the active substance or to any of the excipients. 2) Active or suspected ocular or periocular infection. 3) Active intraocular inflammation.
- Patients participating in other investigational drug trial
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERbrolucizumab
Prospective observational study. There is no treatment allocation. Patients administered brolucizumab, that have started before inclusion of the patient into the study will be enrolled.
Locations(28)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04985487
Related Trials
A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)
NCT0556294716 locations
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
NCT0684754256 locations
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
NCT07007065100 locations
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
NCT0485325150 locations
A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study)
NCT0668081759 locations